A variety of members of the Hh pathway have been found to be affected by mutations in human cancers, such as the inactivating mutations of Patch1 or SUFU or the activating alterations of SMO, Gli1, and Gli2, which lead to signaling pathway activation independently of ligand binding. The gene discussed is GLI1; the disease is cancer.